​​

• 2020 Sep 29
  Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [ 18 F] fluspidine and [ 18 F] fallypride PET study
  Igor D Grachev , Philipp M Meyer , Georg A Becker , Marcus Bronzel , Doug Marsteller 5, Gina Pastino , Ole Voges , Laura Rabinovich , Helena Knebel , Franziska Zientek, Michael Rullmann, Bernhard Sattler, Marianne Patt , Thilo Gerhards, Maria Strauss, Andreas Kluge, Peter Brust, Juha-Matti Savola, Mark F Gordon, Michal Geva, Swen Hesse, Henryk Barthel, Michael R Hayden , Osama Sabri ​
  European Journal of Nuclear and Molecular Medicine (EJNMMI)

• Link:  

​

• 2020 June 5
  Additional Safety and Exploratory Efficacy Data at 48 and 60 Months From Open-HART,
  an Open-Label Extension Study of Pridopidine in Huntington Disease
  Andrew McGarry , Peggy Auinger , Karl Kieburtz , Michal Geva , Munish Mehra , Victor Abler , Igor D Grachev , Mark Forrest Gordon , Juha-Matti Savola , Sanjay Gandhi , Spyridon Papapetropoulos , Michael Hayden
  Journal of Huntingtons Disease
  ​Link: https://pubmed.ncbi.nlm.nih.gov/32508327/

​

• 2019 Sep
  Pridopidine Protects Neurons from Mutant-Huntingtin Toxicity via the Sigma-Receptor.
  Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA.
  Neurobiology of disease​
  Link: https://www.ncbi.nlm.nih.gov/pubmed/31108174​

​

• 2019 May 16
  Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease
  Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA.
  Frontiers in Cellular Neuroscience​
  Link: https://www.ncbi.nlm.nih.gov/pubmed/31156395
   

• 2019 Mar 1
  Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model
  Ariel Ionescu, Tal Gradus, Topaz Altman, Roy Maimon, Noi Saraf Avraham, Michal Geva, Michael Hayden, Eran Perlson.
  Cell Death & Disease
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/30824685

​

• 2019 Feb 12
  Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
  Veronica Francardo, Michal Geva, Francesco Bez, Quentin Denis, Lilach Steiner, Michael R. Hayden, M. Angela Cenci.
  Neurotherapeutics
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/30756361

​

• 2018 Dec 27
  Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.
  Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, Hayden M, Bezprozvanny I.
  Neurobiology of Disease
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/30594810

​

• 2018 Dec 21
  Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
  Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.
  Movement Disorders
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/30575996

​

• 2018 May 21
  Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
  Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.
  Molecular Neurodegeneration
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/29783994 

​

• 2017 Dec 7
  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
  Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.
  Journal of Clinical Investigation
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/29212949 

​

• 2017 Jan
  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
  Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I.
  Neurobiology of Disease
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/27818324
   

• 2016 Sep 15
  Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
  Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.
  Human Molecular Genetics
  ​Link: https://www.ncbi.nlm.nih.gov/pubmed/27466197
   

​

Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS

READ MORE >

Presentation by Dr. Michael Hayden at the Jefferies
Virtual Conference 

03
JUNE

2020

SLIDES >

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General

READ MORE >

MEDIA